[Goose]

Regeneron’s anti-SARS-CoV-2 antibody cocktail has significantly reduced medical visits in ambulatory COVID-19 patients. The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

The downside is that this is an IV antibody cocktail, but you could imagine a case where high risk patients who have been exposed get the cocktail as prophylaxis.  Cutting the hospitalization rate by over half is real progress.



BC

Indeed a cut of over 50% is real progress. It may be that with dosage/formulation tweaks and the like they can do even better. Let's hope so, because it looks like the USA ( and the rest of the Western world) is really going to need it.

[Goose]

Regeneron’s anti-SARS-CoV-2 antibody cocktail has significantly reduced medical visits in ambulatory COVID-19 patients. The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

The downside is that this is an IV antibody cocktail, but you could imagine a case where high risk patients who have been exposed get the cocktail as prophylaxis.  Cutting the hospitalization rate by over half is real progress.



BC

Indeed a cut of over 50% is real progress. It may be that with dosage/formulation tweaks and the like they can do even better. Let's hope so, because it looks like the USA ( and the rest of the Western world) is really going to need it.